Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer

Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer VOLUME 30  NUMBER 15  MAY 20 2012 EDITORIAL JOURNAL OF CLINICAL ONCOLOGY Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer Anne F. Schott and Daniel F. Hayes, University of Michigan, Ann Arbor, MI See accompanying article on page 1796 “Most controversies would soon be ended, if those engaged residual disease after neoadjuvant chemotherapy is associated with 2,16-18 in them would first accurately define their terms, and then long-term prognosis. However, there has been little if any agree- adhere to their definitions.” ment regarding the precise definition of pCR. —Tryon Edwards In the article that accompanies this editorial, von Minckwitz et al address this controversy in a review of their experience with more Preoperative or neoadjuvant chemotherapy is an option in patients than 6,000 patients treated in a series of seven prospectively conducted with early-stage breast cancer. Neoadjuvant treatment has been com- clinical trials of neoadjuvant anthracycline and taxane–based chemo- pared with standard, postoperative adjuvant chemotherapy with the therapy (some including trastuzumab). They compared multiple ex- dual goals of improving survival and facilitating local therapies. Un- isting definitions of pCR to determine how robustly each definition fortunately, neoadjuvant chemotherapy does not seem to improve serves as a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Wolters Kluwer Health

Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer

Loading next page...
 
/lp/wolters-kluwer-health/defining-the-benefits-of-neoadjuvant-chemotherapy-for-breast-cancer-rmmDweNEoY

References (31)

Publisher
Wolters Kluwer Health
Copyright
(C) 2012 American Society of Clinical Oncology
ISSN
0732-183X
eISSN
1527-7755
DOI
10.1200/JCO.2011.41.3161
Publisher site
See Article on Publisher Site

Abstract

VOLUME 30  NUMBER 15  MAY 20 2012 EDITORIAL JOURNAL OF CLINICAL ONCOLOGY Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer Anne F. Schott and Daniel F. Hayes, University of Michigan, Ann Arbor, MI See accompanying article on page 1796 “Most controversies would soon be ended, if those engaged residual disease after neoadjuvant chemotherapy is associated with 2,16-18 in them would first accurately define their terms, and then long-term prognosis. However, there has been little if any agree- adhere to their definitions.” ment regarding the precise definition of pCR. —Tryon Edwards In the article that accompanies this editorial, von Minckwitz et al address this controversy in a review of their experience with more Preoperative or neoadjuvant chemotherapy is an option in patients than 6,000 patients treated in a series of seven prospectively conducted with early-stage breast cancer. Neoadjuvant treatment has been com- clinical trials of neoadjuvant anthracycline and taxane–based chemo- pared with standard, postoperative adjuvant chemotherapy with the therapy (some including trastuzumab). They compared multiple ex- dual goals of improving survival and facilitating local therapies. Un- isting definitions of pCR to determine how robustly each definition fortunately, neoadjuvant chemotherapy does not seem to improve serves as a

Journal

Journal of Clinical OncologyWolters Kluwer Health

Published: May 20, 2012

There are no references for this article.